{
     "PMID": "22982863",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20121228",
     "LR": "20161125",
     "IS": "1873-3468 (Electronic) 0014-5793 (Linking)",
     "VI": "586",
     "IP": "20",
     "DP": "2012 Oct 19",
     "TI": "Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.",
     "PG": "3737-45",
     "LID": "10.1016/j.febslet.2012.09.004 [doi] S0014-5793(12)00706-5 [pii]",
     "AB": "Growing evidence suggests that Alzheimer disease (AD) origins in vascular lesions. As the crucial mediator of vascular pathology, angiotensin II-induced significant amyloid production in our laboratory, although amyloid neurotoxicity depended on phosphorylated tau (p-tau) in recent studies. In the present study, p-tau levels were significantly elevated by central angiotensin II via glycogen synthase kinase 3beta (GSK 3beta) and other tau kinases. Moreover, angiotensin II-induced cognitive impairment and tau phosphorylation was attenuated by losartan and a GSK 3beta inhibitor. These findings implicate Ang II as a crucial mediator of AD pathology and a link between cardiovascular events and AD.",
     "CI": [
          "Copyright (c) 2012 Federation of European Biochemical Societies. Published by",
          "Elsevier B.V. All rights reserved."
     ],
     "FAU": [
          "Tian, Minjie",
          "Zhu, Donglin",
          "Xie, Wei",
          "Shi, Jingping"
     ],
     "AU": [
          "Tian M",
          "Zhu D",
          "Xie W",
          "Shi J"
     ],
     "AD": "Department of Neurology, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, PR China.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20120913",
     "PL": "England",
     "TA": "FEBS Lett",
     "JT": "FEBS letters",
     "JID": "0155157",
     "RN": [
          "0 (Indoles)",
          "0 (Maleimides)",
          "0 (SB 216763)",
          "0 (tau Proteins)",
          "11128-99-7 (Angiotensin II)",
          "9Y8NXQ24VQ (Propranolol)",
          "EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)",
          "EC 2.7.11.1 (Gsk3b protein, rat)",
          "EC 2.7.11.26 (Glycogen Synthase Kinase 3)",
          "JMS50MPO89 (Losartan)"
     ],
     "SB": "IM",
     "EIN": [
          "FEBS Lett. 2013 Mar 18;587(6):818"
     ],
     "MH": [
          "Alzheimer Disease/*metabolism/pathology/physiopathology",
          "Angiotensin II/administration & dosage/metabolism/*pharmacology",
          "Animals",
          "Brain/*drug effects/*metabolism/pathology/physiopathology",
          "Cognition/drug effects",
          "Dose-Response Relationship, Drug",
          "Enzyme Activation/drug effects",
          "Glycogen Synthase Kinase 3/metabolism",
          "Glycogen Synthase Kinase 3 beta",
          "Hippocampus/drug effects/metabolism/pathology/physiopathology",
          "Indoles/pharmacology",
          "Losartan/pharmacology",
          "Male",
          "Maleimides/pharmacology",
          "Phosphorylation/drug effects",
          "Propranolol/pharmacology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Signal Transduction/drug effects",
          "tau Proteins/*metabolism"
     ],
     "EDAT": "2012/09/18 06:00",
     "MHDA": "2012/12/29 06:00",
     "CRDT": [
          "2012/09/18 06:00"
     ],
     "PHST": [
          "2012/07/22 00:00 [received]",
          "2012/08/29 00:00 [revised]",
          "2012/09/01 00:00 [accepted]",
          "2012/09/18 06:00 [entrez]",
          "2012/09/18 06:00 [pubmed]",
          "2012/12/29 06:00 [medline]"
     ],
     "AID": [
          "S0014-5793(12)00706-5 [pii]",
          "10.1016/j.febslet.2012.09.004 [doi]"
     ],
     "PST": "ppublish",
     "SO": "FEBS Lett. 2012 Oct 19;586(20):3737-45. doi: 10.1016/j.febslet.2012.09.004. Epub 2012 Sep 13.",
     "term": "hippocampus"
}